Cargando…

Melphalan transport into human malignant lymphoid cells differs from the murine equivalent in vitro.

Detalles Bibliográficos
Autores principales:	Millar, B. C., Maitland, J. A., Millar, J. L., Bell, J. B.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1989
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247227/ https://www.ncbi.nlm.nih.gov/pubmed/2736204

Ejemplares similares

Verapamil potentiation of melphalan cytotoxicity and cellular uptake in murine fibrosarcoma and bone marrow.
por: Robinson, B. A., et al.
Publicado: (1985)

Effects of verapamil and alcohol on blood flow, melphalan uptake and cytotoxicity, in murine fibrosarcomas and human melanoma xenografts.
por: Robinson, B. A., et al.
Publicado: (1986)

Epidermal growth factor (hEGF) has no effect on murine intestine epithelial damage and regeneration after melphalan.
por: Robinson, B. A., et al.
Publicado: (1985)

Melphalan uptake in relation to vascular and extracellular space of human lung-tumour xenografts.
por: Wist, E., et al.
Publicado: (1981)

Effect of high-dose melphalan on marrow and intestinal epithelium in mice pretreated with cyclophosphamide.
por: Millar, J. L., et al.
Publicado: (1978)

Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation.
por: Cornbleet, M. A., et al.
Publicado: (1983)

Activation of murine 'T' lymphomas in the presence of a human myeloma cell line, RPMI-8226, in vivo.
por: Millar, B. C., et al.
Publicado: (1988)

Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan.
por: McElwain, T. J., et al.
Publicado: (1979)

The effects of melphalan and misonidazole on the vasculature of a murine sarcoma.
por: Murray, J. C., et al.
Publicado: (1987)

Cyclophosphamide priming reduces intestinal damage in man following high dose melphalan chemotherapy.
por: Selby, P. J., et al.
Publicado: (1987)

Oral Melphalan Therapy in Advanced Malignant Disease
por: Clifford, Peter, et al.
Publicado: (1963)

Synthesis and In Vitro Activity of Novel Melphalan Analogs in Hematological Malignancy Cells
por: Poczta, Anastazja, et al.
Publicado: (2022)

Clonal variation in the sensitivity of a murine mammary carcinoma to melphalan.
por: McMillan, T. J., et al.
Publicado: (1986)

The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.
por: Scott, R. N., et al.
Publicado: (1992)

2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies.
por: Hickish, T., et al.
Publicado: (1993)

Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan.
por: Moscow, J. A., et al.
Publicado: (1993)

Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione.
por: Barnouin, K., et al.
Publicado: (1998)

Potentiation of melphalan activity against a murine tumour by nitroimidazole compounds.
por: Sheldon, P. W., et al.
Publicado: (1982)

Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies
por: Thompson, J F, et al.
Publicado: (2001)

Evidence that multiple myeloma may be regulated by homeostatic control mechanisms: correlation of changes in the number of clonogenic myeloma cells in vitro with clinical response.
por: Maitland, J. A., et al.
Publicado: (1990)

The proliferation of multiple myeloma colonies (MY-CFUc) in vitro is independent of prognosis and is not associated with mutated N- or K-ras alleles in human bone marrow aspirates.
por: Millar, B. C., et al.
Publicado: (1995)

Nitric oxide enhancement of melphalan-induced cytotoxicity.
por: Cook, J. A., et al.
Publicado: (1997)

Chemical modification of melphalan as a key to improving treatment of haematological malignancies
por: Gajek, Arkadiusz, et al.
Publicado: (2020)

Factors influencing the chemosensitization of melphalan by misonidazole.
por: Randhawa, V. S., et al.
Publicado: (1985)

The effect of hyperthermia in combination with melphalan on drug-sensitive and drug-resistant CHO cells in vitro.
por: Bates, D. A., et al.
Publicado: (1990)

Cytotoxic efficacy of filanesib and melphalan combination is governed by sequence of treatment in human myeloma cells
por: Norris, E J, et al.
Publicado: (2016)

The effect of systemic hyperthermia on melphalan pharmacokinetics in mice.
por: Honess, D. J., et al.
Publicado: (1985)

The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse.
por: Hinchliffe, M., et al.
Publicado: (1983)

2',5'-Oligoadenylate synthetase levels in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b do not correlate with clinical response.
por: Millar, B. C., et al.
Publicado: (1995)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019)

Lymphocyte targeted ricin as a potential therapy for lymphoid malignancy. I. Targeting efficiency.
por: Ramsden, C. S., et al.
Publicado: (1991)

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Rodriguez, Tulio E., et al.
Publicado: (2016)

Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration
por: Ge, Qunfang, et al.
Publicado: (2022)

Flurbiprofen, a non-steroid anti-inflammatory agent, protects cells against hypoxic cell radiosensitizers in vitro.
por: Millar, B. C., et al.
Publicado: (1981)

High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma.
por: Pritchard, J., et al.
Publicado: (1982)

Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb.
por: Klaase, J. M., et al.
Publicado: (1994)

Evidence for different mechanisms of ‘unhooking’ for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples
por: Spanswick, Victoria J, et al.
Publicado: (2012)

Repeat administration of high dose melphalan in relapsed myeloma.
por: Mansi, J. L., et al.
Publicado: (1993)

Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine.
por: Stratford, I. J., et al.
Publicado: (1988)

Significance of trogocytosis and exosome-mediated transport in establishing and maintaining the tumor microenvironment in lymphoid malignancies
por: Kawashima, Masaharu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bak2gfncm4at2cnvm38pt2fmfr